SBIR/STTR Research Award

A high-throughput platform for neo-antigen based cancer immunotherapy

Award identifier c3408daefa0e2a4c4c53a84bd40482b47d724e77825a2cd76ee61e0e96f918f4Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$299,917

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ImmuDX LLC
Proposal award date
2018-08-01
Contract end date
2019-07-31
UEI
D6NRPST2VJH5
Solicitation number
PA17-302
Topic code
100

Research abstract

Abstract Critical to the future progress of cancer immunotherapies is the discovery and tracking of T cells specific for cancer cells but not normal tissuesNeo antigen derived from mutations are a group of attractive antigens for cancer immunotherapyBecause they are mutated variants of self antigensthey are immunologically considered as foreign antigens and are not part of the self antigensThusthese cells are able to retain high affinity T cell receptorTCRsbearing cells that are more cytotoxic T cellsNeo antigen based therapieswhether as neo antigen vaccines or using neo antigen specific T cell receptorTCRsequences in TCR re directed adoptive cell transfer therapyhave become very promising in the fight against cancerHoweverone potential complication of neo antigen based therapies is the cross reactivity of neo antigen activated T cells might have toward the wildtype counterpart peptideWT peptideThereforehigh throughput screening for neo antigens that only induce neo antigen specific T cell responses or high throughput screening for neo antigen only TCRs is critical for the wide application of neo antigen based cancer immunotherapy approach in clinical settingsHowevercurrent technology does not permit a quick screening for none WT reactive neo antigens or none WT reactive neo antigen specific T cells from hundreds of neo antigen candidatesUsing a recently developed technology that links TCR specificities to TCR sequences at single cell level in a high throughput mannerwe aim to develop a high throughput platform for screening non cross reactive neo antigens and neo antigen specific TCRs for cancer immunotherapy Narrative Experimentally validating hundreds of neo antigens for therapeutic purpose is challengingSimilar challenge existed for identifying neo antigen specific TCRs quickly and in a high throughput mannerThe proposed technology addresses these challenges and will offer two new capabilities that will transform both cancer immunotherapy research and clinical practice

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2018). Reported award amounts total $882,444. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.